147 related articles for article (PubMed ID: 36029665)
1. Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus.
Zhang X; Liu C; Yang J; Ren H; Zhang J; Chen S; Ren J; Zhou L
Int Immunopharmacol; 2022 Oct; 111():109155. PubMed ID: 36029665
[TBL] [Abstract][Full Text] [Related]
2. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus.
Lindblom J; Beretta L; Borghi MO; ; Alarcón-Riquelme ME; Parodis I
Front Immunol; 2023; 14():1257085. PubMed ID: 38098483
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?
Capper ER; Maskill JK; Gordon C; Blakemore AI
Clin Exp Immunol; 2004 Nov; 138(2):348-56. PubMed ID: 15498048
[TBL] [Abstract][Full Text] [Related]
4. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.
Chun HY; Chung JW; Kim HA; Yun JM; Jeon JY; Ye YM; Kim SH; Park HS; Suh CH
J Clin Immunol; 2007 Sep; 27(5):461-6. PubMed ID: 17587156
[TBL] [Abstract][Full Text] [Related]
5. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
Nordin F; Shaharir SS; Abdul Wahab A; Mustafar R; Abdul Gafor AH; Mohamed Said MS; Rajalingham S; Shah SA
Int J Rheum Dis; 2019 Aug; 22(8):1419-1426. PubMed ID: 31179646
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin-33 (IL-33) in children with active systemic lupus erythematosus: A cross-sectional study.
Abd-Elazeem RI; Abdelnabi HH; Hegab DS; Mohamed WS; Ameen TE
Egypt J Immunol; 2022 Oct; 29(4):148-155. PubMed ID: 36208043
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
El-Banna HS; El Khouly RM; Gado SE
Clin Rheumatol; 2020 May; 39(5):1627-1632. PubMed ID: 31907692
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
9. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.
Sturfelt G; Roux-Lombard P; Wollheim FA; Dayer JM
Br J Rheumatol; 1997 Dec; 36(12):1283-9. PubMed ID: 9448589
[TBL] [Abstract][Full Text] [Related]
10. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.
Italiani P; Manca ML; Angelotti F; Melillo D; Pratesi F; Puxeddu I; Boraschi D; Migliorini P
Arthritis Res Ther; 2018 Feb; 20(1):27. PubMed ID: 29422069
[TBL] [Abstract][Full Text] [Related]
11. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.
Liou LB
Clin Exp Rheumatol; 2003; 21(4):437-44. PubMed ID: 12942694
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus.
Chang DM
Immunol Invest; 1997; 26(5-7):649-59. PubMed ID: 9399106
[TBL] [Abstract][Full Text] [Related]
13. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
[TBL] [Abstract][Full Text] [Related]
14. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.
Thanadetsuntorn C; Ngamjanyaporn P; Setthaudom C; Hodge K; Saengpiya N; Pisitkun P
Sci Rep; 2018 Feb; 8(1):2620. PubMed ID: 29422675
[TBL] [Abstract][Full Text] [Related]
15. Performance of cytokine models in predicting SLE activity.
Ruchakorn N; Ngamjanyaporn P; Suangtamai T; Kafaksom T; Polpanumas C; Petpisit V; Pisitkun T; Pisitkun P
Arthritis Res Ther; 2019 Dec; 21(1):287. PubMed ID: 31842967
[TBL] [Abstract][Full Text] [Related]
16. Increased serum IL-36α and IL-36γ levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis.
Mai SZ; Li CJ; Xie XY; Xiong H; Xu M; Zeng FQ; Guo Q; Han YF
Int Immunopharmacol; 2018 May; 58():103-108. PubMed ID: 29571080
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis.
Hardt U; Larsson A; Gunnarsson I; Clancy RM; Petri M; Buyon JP; Silverman GJ; Svenungsson E; Grönwall C
Arthritis Res Ther; 2018 Feb; 20(1):36. PubMed ID: 29482604
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
Front Immunol; 2018; 9():1250. PubMed ID: 29930551
[TBL] [Abstract][Full Text] [Related]
19. Relationship of serum inflammatory cytokines with anemia and vascular endothelial function in children with systemic lupus erythematosus.
Yang Y; Che Y; Yang L
Clin Hemorheol Microcirc; 2019; 73(2):299-306. PubMed ID: 30909195
[TBL] [Abstract][Full Text] [Related]
20. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients.
Liou LB
Clin Exp Rheumatol; 2001; 19(5):515-23. PubMed ID: 11579710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
